Literature DB >> 11027078

Recent advances in gestational trophoblastic disease.

J O Schorge1, D P Goldstein, M R Bernstein, R S Berkowitz.   

Abstract

Recent advances have increased our understanding of gestational trophoblastic disease, and epidemiologic studies have demonstrated that there are important differences in risk factors for complete and partial mole. Complete moles are now increasingly being diagnosed in the first trimester, affecting their clinical presentation and pathologic characteristics. While important advances have been made in chemotherapy, it is now recognized that etoposide is associated with a risk of second tumors. Several studies have advanced understanding of the molecular biology of gestational trophoblastic disease, and this is important for the eventual development of new and innovative therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027078

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

1.  Prophylactic Chemotherapy with Methotrexate Leucovorin in High-Risk Hydatidiform Mole.

Authors:  Soheila Aminimoghaddam; Fatemeh Mahmoudzadeh; Marzieh Mohammadi
Journal:  Asian Pac J Cancer Prev       Date:  2020-06-01

2.  miR-30a targets STOX2 to increase cell proliferation and metastasis in hydatidiform moles via ERK, AKT, and P38 signaling pathways.

Authors:  Zhenzhen Guo; Chenyu Zhu; Ying Kong; Dong Li; Linlin Sui; Youhui Wang; Zhen Li; Lu Wang; Jianhui Fan; Yuefei Xu; Na Zou
Journal:  Cancer Cell Int       Date:  2022-03-04       Impact factor: 5.722

3.  Frequency of molar pregnancies in health care centers of tehran, iran.

Authors:  Alireza Almasi; Fariba Almassinokiani; Peyman Akbari
Journal:  J Reprod Infertil       Date:  2014-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.